Where I see patients (1)
A prospective evaluation of neck and shoulder function following treatments of early-stage human papillomavirus-associated oropharynx cancer.
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients Wit...
For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or M...
Treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants...
The occurrence of the following toxicities, if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration: Grade 4 nonhematologic toxicity (not laboratory) Grade 4 hematologic to...
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma ...
TEAE's are defined as Adverse Events (AEs) with onset after date-time of first dose, or medical conditions present prior to the start of IMP but increased in severity or relationship after date-time of first dose of IMP.